Administration of Beta-Emitting Anti-CD37 Radioimmunoconjugate Lutetium (177Lu) Lilotomab Satetraxetan as Weekly Multiple Injections Increases Maximum Tolerated Activity in Nude Mice with Non- Hodgkin Lymphoma Xenografts

Helèn Heyerdahl(Nordic Nanovector (Norway)), Jostein Dahle(Oslo University Hospital), Ada H. V. Repetto‐Llamazares(Nordic Nanovector (Norway))
Journal of Cancer Biology and Therapeutics
September 11, 2018
Cited by 1


Related Papers